The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
Open accessAbstract
The key nuclear export protein CRM1/XPO1 may represent a promising novel therapeutic target in human multiple myeloma (MM). Here we showed that chromosome region maintenance 1 (CRM1) is highly expressed in patients with MM, plasma cell leukemia cells and increased in patient cells resistant to bortezomib treatment. CRM1 expression also correlates with increased lytic bone and shorter survival. Importantly, CRM1 knockdown inhibits MM cell viability. Novel, oral, irreversible selective inhibitors of nuclear export (SINEs) targeting CRM1 (KPT-185, KPT-330) induce cytotoxicity against MM cells (ED50<200 nM), alone and cocultured with bone marrow stromal cells (BMSCs) or osteoclasts (OC). SINEs trigger nuclear accumulation of multiple CRM1 cargo tumor suppressor proteins followed by growth arrest and apoptosis in MM cells. They further block c-myc, Mcl-1, and nuclear factor κB (NF-κB) activity. SINEs induce proteasome-dependent CRM1 protein degradation; concurrently, they upregulate CRM1, p53-targeted, apoptosis-related, anti-inflammatory and stress-related gene transcripts in MM cells. In SCID mice with diffuse human MM bone lesions, SINEs show strong anti-MM activity, inhibit MM-induced bone lysis and prolong survival. Moreover, SINEs directly impair osteoclastogenesis and bone resorption via blockade of RANKL-induced NF-κB and NFATc1, with minimal impact on osteoblasts and BMSCs. These results support clinical development of SINE CRM1 antagonists to improve patient outcome in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081240 · Cited by 109
Self-citationRetractedTakayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J.-I., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00369-6 · Cited by 2,701
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,514
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Self-citationUnderstanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Self-citationShaughnessy, J. D., Zhan, F., Burington, B. E., Huang, Y., Colla, S., Hanamura, I., Stewart, J. P., Kordsmeier, B., Randolph, C., Williams, D. R., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038430 · Cited by 914
Self-citationDC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells
Yagi, M., Miyamoto, T., Sawatani, Y., Iwamoto, K., Hosogane, N., Fujita, N., Morita, K., Ninomiya, K., Suzuki, T., Miyamoto, K., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050645 · Cited by 890
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways
Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K. H., Han, J., Chittenden, T., Ihle, J. N., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00244-7 · Cited by 879
Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558
Tai, Y.-T., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2008) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 473
Self-citation
Cited by
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationGenomic and molecular characterization of esophageal squamous cell carcinoma
Lin, D.-C., Hao, J.-J., Nagata, Y., Xu, L., Shang, L., Meng, X., Sato, Y., Okuno, Y., Varela, A. M., Ding, L.-W., et al. (2014) · Nature Genetics · doi:10.1038/ng.2935 · Cited by 626
Self-citationTai, Y.-T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 484
Self-citationTai, Y.-T., Acharya, C., An, G., Moschetta, M., Zhong, M. Y., Feng, X., Cea, M., Cagnetta, A., Wen, K., van Eenennaam, H., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691162 · Cited by 350
Self-citationGrosicki, S., Simonova, M., Spicka, I., Pour, L., Kriachok, I., Gavriatopoulou, M., Pylypenko, H., Auner, H. W., Leleu, X., Doronin, V., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32292-3 · Cited by 335
Self-citationChim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/leu.2017.329 · Cited by 305
Self-citationThe nuclear export protein XPO1 — from biology to targeted therapy
Azmi, A. S., Uddin, M. H., & Mohammad, R. M. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00442-4 · Cited by 279
Nucleo-cytoplasmic transport as a therapeutic target of cancer
Gravina, G. L., Senapedis, W., McCauley, D., Baloglu, E., Shacham, S., & Festuccia, C. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0085-1 · Cited by 275
Self-citationJiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219
“Following lentiviral transduction, we selected three p53-mutated MM cell lines (RPMI8226, U266, JJN3), 24 which represent high risk and drug resistance groups, based upon 4 six-fold higher CD38 on the cell membrane than their paired parental lines (Figure 1a, Supplementary Figure S1A).”
Self-citationRetractedHistone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159
Self-citationYu, T., Chaganty, B., Lin, L., Xing, L., Ramakrishnan, B., Wen, K., Hsieh, P. A., Wollacott, A., Viswanathan, K., Adari, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00378-z · Cited by 43
Self-citation
Metadata
- Authors
- Tai, Y.-T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M. Y., Cea, M., Tannenbaum, D., Cagnetta, A., Reagan, M., Munshi, A. A., Senapedis, W., Saint-Martin, J.-R., Kashyap, T., Shacham, S., Kauffman, M., Gu, Y., Wu, L., Ghobrial, I., Zhan, F., Kung, A. L., Schey, S. A., Richardson, P., Munshi, N. C., & Anderson, K. C.
- Venue
- Leukemia
- Published
- 2013-04-16
- Volume
- 28
- Issue
- 1
- Pages
- 155-165
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2094088075
- Cited by
- 308
- References
- 42
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.